

Claim 1 (currently amended): A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide,

wherein the first polypeptide comprises a polypeptide sequence with at least 85% homology to an extracellular portion ~~at least a region~~ of a glycoprotein Iba polypeptide of SEQ ID NO:1, and said first polypeptide binds a polypeptide selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin; and

wherein the second polypeptide comprises at least a region of an immunoglobulin heavy chain polypeptide.

Claim 2 (cancelled)

Claim 3 (currently amended): The fusion polypeptide of claim 2 1, wherein said first polypeptide binds to ~~one or more~~ at least two of the polypeptides selected from the group consisting of a leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

Claim 4 (cancelled)

Claim 5 (currently amended): The fusion polypeptide of claim 1, wherein said polypeptide comprises SEQ ID NO:4 5.

Claim 6 (currently amended): The fusion polypeptide of claim 1, wherein said ~~first polypeptide~~ fusion polypeptide is more resistant to proteolysis than a wild-type GP Ib α polypeptide.

Claim 7. (original): The fusion polypeptide of claim 1, wherein said first polypeptide binds with higher affinity to a von ~~Willebrand~~ Willebrand factor polypeptide than a wild-type glycoprotein Ib α polypeptide binds to said von ~~Willebrand~~ Willebrand factor polypeptide.

Claim 8 (original): The fusion polypeptide of claim 7 1, wherein said first polypeptide comprises at least one of the amino acid substitutions G233V or M239V relative to the amino acid sequence of a wild-type GPIb α polypeptide.

Claim 9 (currently amended): The fusion polypeptide of claim 7 1, wherein said first polypeptide comprises the amino acid substitutions G233V and M239V relative to the amino acid sequence of a wild-type GPIb α polypeptide.

Claim 10 (cancelled)

Claim 11 (original): The fusion polypeptide of claim 10 1, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

Claim 12 (original): The fusion polypeptide of claim 11, wherein said second polypeptide has less effector function than the effector function of a Fc region of a wild-type immunoglobulin heavy chain.

Claim 13 (original): The fusion polypeptide of claim 12, wherein said second polypeptide binds with low or no affinity to a Fc receptor.

Claim 14 (original): The fusion polypeptide of claim 12, wherein said second polypeptide binds with low or no affinity to complement protein C1q.

Claims 15-19 (cancelled)

Claim 20 (currently amended): The fusion polypeptide of claim 1, wherein said fusion polypeptide comprises the amino acid sequence of ~~GP1b302-Ig~~ GPIb α 302-Ig (SEQ ID NO:1), ~~GPIb302/2A-Ig~~ GPIb α 302/2A-Ig (SEQ ID NO:2), ~~GP1b302/4X-Ig~~ GPIb α 302/4X-Ig (SEQ ID NO:3), ~~GP1b290-Ig~~ GPIb α 290-Ig (SEQ ID NO:4), ~~GP1b290/2V-Ig~~ GPIb α 290/2V-Ig (SEQ ID NO:5.) and or ~~GP1b290/1A-Ig~~ GPIb α 290/1A-Ig (SEQ ID NO:6).

Claim 21 (original): A multimeric polypeptide comprising the fusion polypeptide of claim 1.

Claim 22 (original): The multimeric polypeptide of claim 21, wherein said multimeric polypeptide is a dimer.

Claims 23-26 (cancelled)

Claim 27 (original): A pharmaceutical composition comprising the fusion polypeptide of claim 1.

Claim 28-53 (cancelled)

Claim 54 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds at least three polypeptides selected from the group consisting of leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

Claim 55 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds leukocyte integrin Mac-1 polypeptide, von Willebrand factor, thrombin and P-selectin.

Claim 56 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds leukocyte integrin Mac-1 polypeptide.

Claim 57 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds von Willebrand factor.

Claim 58 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds thrombin.

Claim 59 (new) The fusion polypeptide of claim 1, wherein said first polypeptide binds P-selectin.

Claim 60 (new): A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide,

wherein the first polypeptide consists essentially of a polypeptide sequence with at least 85% homology to an extracellular portion of a glycoprotein Iba polypeptide of SEQ ID NO:1 and said first polypeptide binds von Willebrand factor polypeptide; and

wherein the second polypeptide consists essentially of an immunoglobulin heavy chain polypeptide, wherein said immunoglobulin heavy chain polypeptide comprises a Fc region.

Claim 61 (new): A polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Claim 62 (new): The polypeptide of claim 61, wherein the amino acid sequence of the polypeptide consists essentially of SEQ ID NO:1.